Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
|Podcasts|February 5, 2020
Analyzing the Application of Precision Medicine in Austin
Author(s)OncLive Staff
We traveled to Austin, Texas, for a State of the Science Summit™ on Precision Medicine, which featured insights from the Texas Oncology faculty.
Advertisement
We recently traveled to Austin, Texas, for an OncLive® State of the Science Summit™ on Precision Medicine. At the meeting, faculty from Texas Oncology provided updates on precision medicine initiatives in lung cancer and pancreatic cancer, including biomarkers and molecular testing.
Interested in attending an upcoming OncLive® State of the Science Summit™ in your area?
Advertisement
Related to this article
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.
UCSF experts will present key research at the 31st Society for Neuro-Oncology Annual Meeting.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
2
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
3
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
4
Expanding Clinical Trial Access Through Community Oncology
5